Novartis Media Relations E-mail: media.relations@novartis.com Novartis Investor Relations Central investor relations line: +41 61 ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

Q4 2024 Management View CEO Thomas Lingelbach highlighted that Valneva achieved double-digit year-on-year sales growth, with total product sales surpassing €160 million for 2024, in line with guidance ...

The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...

Cassava Sciences explores simufilam's potential for seizures in tuberous sclerosis. Results for Alzheimer's trials expected ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with ...

Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Discover three undervalued biotech stocks with strong assets, solid cash reserves, and major catalysts ahead. Click for the ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in ...

Q4 2024 Management View CEO Eef Schimmelpennink highlighted 2024 as a transformative year, marked by significant milestones, including the completion of the Phase 3 CLARITY study, submission and ...